Gadoxetate disodium-enhanced hepatic MRI: Dose-dependent contrast dynamics of hepatic parenchyma and portal vein

American Journal of Roentgenology

Volumn 196, Issue 1, 2011, Pages

  Feuerlein, Sebastian ^a,b   Boll, Daniel T ^b   Gupta, Rajan T ^b   Ringe, Kristina I ^c   Marin, Daniele ^b   Merkle, Elmar M ^b  

^a UNIVERSITY OF ULM   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Contrast agent; Gadolinium; Liver; MRI

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER DISEASE; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LINEAR MODELS; LIVER DISEASES; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PORTAL VEIN; RETROSPECTIVE STUDIES;

EID: 78650805205     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4387     Document Type: Article

References (24)

1. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992; 183:1-11
2. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199:177-183
3. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59-67
4. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40:715-724 (Pubitemid 41546838)
5. Maetani Y, Itoh K, Kojima N, et al. Portal vein anomaly associated with deviation of the ligamentum teres to the right and malposition of the gallbladder. Radiology 1998; 207:723-728
6. McNulty JG, Khosa F. Absence of bifurcation of the portal vein. Radiology 1999; 211:589-590
7. Gallego C, Velasco M, Marcuello P, Tejedor D, De Campo L, Friera A. Congenital and acquired anomalies of the portal venous system. RadioGraphics 2002; 22:141-159
8. Coursey CA, Nelson RC, Weber PW, et al. Contrast material administration protocols for 64-MDCT angiography: altering volume and rate and use of a saline chaser to better match the imaging window - physiologic phantom study. AJR 2009; 193:1568-1575
9. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR 2010; 195:13-28
10. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40:736-741
11. Dodd GD 3rd, Memel DS, Baron RL, Eichner L, Santiguida LA. Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? AJR 1995; 165:573-577
12. Manzanet G, Sanjuan F, Orbis P, et al. Liver transplantation in patients with portal vein thrombosis. Liver Transpl 2001; 7:125-131 (Pubitemid 32166518)
13. Ueda K, Matsui O, Kawamori Y, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998; 206:161-166 (Pubitemid 28063001)
14. Koike Y, Nakagawa K, Shiratori Y, et al. Factors affecting the prognosis of patients with hepatocellular carcinoma invading the portal vein: a retrospective analysis using 952 consecutive HCC patients. Hepatogastroenterology 2003;50: 2035-2039 (Pubitemid 37467989)
15. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67
16. Pirisi M, Avellini C, Fabris C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol 1998; 124:397-400
17. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461-469 (Pubitemid 44142456)
18. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699
19. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311-330
20. Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007; (7 spec no A):S24-S27
21. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64
22. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792
23. Bian J, Sha L, Yang C, Sun CS. Three-dimensional dynamic contrast-enhanced MR angiography for evaluating recipient vessels in orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7:476-480
24. Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. RadioGraphics 2008; 28:1983-1998